MRE-269-d 7 is deuterium labeled MRE-269 . MRE-269 is an active metabolite of selexipag, and acts as a selective IP receptor agonist.
In Vitro
Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs. MCE has not independently confirmed the accuracy of these methods. They are for reference only.